Autoimmune Antibodies and Recurrence-Free Interval in Melanoma Patients Treated With Adjuvant Interferon-Reference-Cited by-同舟云学术

Autoimmune Antibodies and Recurrence-Free Interval in Melanoma Patients Treated With Adjuvant Interferon

Published:2009-06 Issue:12 Volume:101 Page:869-877
ISSN:0027-8874
Container-title:JNCI: Journal of the National Cancer Institute
language:en
Short-container-title:

Author:

Bouwhuis Marna G.,Suciu Stefan,Collette Sandra,Aamdal Steinar,Kruit Wim H.,Bastholt Lars,Stierner Ulrika,Salès François,Patel Poulam,Punt Cornelis J. A.,Hernberg Micaela,Spatz Alain,ten Hagen Timo L. M.,Hansson Johan,Eggermont Alexander M. M.,

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/101/12/869/18614215/djp132.pdf

Reference26 articles.

1. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma;Kirkwood;Clin Cancer Res,2004

2. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials;Wheatley;Cancer Treat Rev,2003

3. Interferon alpha as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials;Wheatley;J Clin Oncol,2007

4. Prognostic significance of autoimmunity during treatment of melanoma with interferon;Gogas;N Engl J Med,2006

5. Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha;Satzger;Int J Cancer,2007

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Placebo immune-related adverse events (irAEs): A neglected phenomenon in cancer immunotherapy trials;European Journal of Cancer;2024-09

2. Prognostic and Diagnostic Significance of Chemokines and Cytokines in Cancer;Cytokine and Chemokine Networks in Cancer;2023

3. A B‐cell or a key player? The different roles of B‐cells and antibodies in melanoma;Pigment Cell & Melanoma Research;2022-03-04

4. Expression of Autoimmunity-Related Genes in Melanoma;Cancers;2022-02-16

5. Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054;Journal for ImmunoTherapy of Cancer;2022-01